EDAN Instruments Reveals Upgrades to Acclarix LX9 Ultrasound System
System and upgrades awaiting U.S. FDA clearance
DUBAI-China-based global healthcare company EDAN Instruments, Inc., unveiled its next-generation diagnostic ultrasound system Acclarix LX9 during Arab Health 2020.
The Acclarix LX9 system is currently awaiting 510(k) clearance from the U.S. Food and Drug Administration.
With Acclarix LX9, EDAN is adding artificial intelligence (AI) technologies to its existing ultrasound family. New features include eOB, eLV, eFollicle, eVolFlow, and eNT, all of which, according to Alice Bai, EDAN’s ultrasound clinical application manager, are designed to optimize workloads for sonographers in a various departments, such as obstetrics, gynecology, cardiology, and general surgery.
In addition to the additional AI features, LX9 also offers a 21.5-inch, high resolution LCD screen equipped with a new EIS+ platform that improves image quality. The integrated user interface can also be rotated 180 degrees.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
